BioSpace News Archive

Turn Therapeutics, a biotechnology company specializing in advanced wound care and infection control, today announced the results of its Phase 2B, placebo controlled trial of Hexagen Antimicrobial Ointment in treating mild to moderate infected COVID-19 patients.

Renovacor, Inc., an early–stage biotechnology company developing adeno-associated virus –based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, announced the appointment of Matt Killeen, Ph.D., as chief scientific officer, effective as of September 1, 2021.

Vertex Pharmaceuticals Incorporated (Canada) (Nasdaq: VRTX) today announced that Health Canada has granted Marketing Authorization for PrKALYDECO®

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to potentially create new treatments that make a meaningful difference in patients’ lives, today announced that the U.S. Food and Drug Administration (FDA) has approved SKYTROFA

Researchers at the University of Central Florida College of Medicine in Orlando, Florida, have discovered a new technology to accelerate wound-healing using specially designed ceramics wrapped in a rubber blanket fabricated for them by Gladiator Therapeutics.

Eight early-stage health and life sciences companies from each of the four Atlantic Canadian provinces have been chosen as the 2021 BioInnovation Challenge (BIC) semi-finalists.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the BD Veritor™ At-Home COVID-19 Test

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients’ lives, today announced financial results for the second quarter ended June 30, 2021.

Exelixis, Inc. (Nasdaq: EXEL) today announced Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX® (cabozantinib) in Japan.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced two oral presentations of clinical data will be presented at the upcoming European Society for Medical Oncology Congress (ESMO) 2021,